They expect it to be well oversubscribed so that is good newsThough the market is pretty hot so they are coming out of the woodwork There is another from DML in my inbox
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%